UPDATE: Piper Jaffray Downgrades Novan (NOVN) to Neutral; Sets 'Street Low' $0.50 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Novan (NOVN) Phase 3 Trials of SB206 for Molluscum Contagiosum Didn't Achieve Primary Endpoint
January 2, 2020 4:17 PM ESTNovan, Inc. (the Company or Novan) (Nasdaq: NOVN) today announced top-line efficacy results from its Phase 3 B-SIMPLE program with SB206 for the treatment of molluscum contagiosum (molluscum). Statistical significance was not achieved for the primary endpoint in either B-SIMPLE1 or B-SIMPLE2, however multiple sensitivity analyses are supportive and consistent across both studies and support a potential path forward for the asset. The two trials are ongoing, awaiting 24-week safety data, thus the top-line results are for efficacy data only.
Summary of Top-Line Efficacy Data and SB206 Program:
SB206 did not... MoreNovan (NOVN) Halted, News Pending
January 2, 2020 4:10 PM ESTNovan (NASDAQ: NOVN) Halted, News Pending
... More
